IASPharma’s Post

A lot is happening in #Brussels these days! I had the privilege of attending the #EFPIA conference, “Imagine a Healthier, More Competitive Europe.” I joined leaders from the #pharmaceutical industry, policymakers, patient advocates, and #healthcare experts, including: - Nathalie Moll, Director General, EFPIA - Lars Fruergaard Jørgensen, EFPIA President and CEO of Novo Nordisk - Hosams Abu Meri, Minister of Health, Republic of Latvia who discussed critical health issues facing Europe, such as ensuring faster, more equitable access to medicines and transforming the EU into an #innovation hub. Key questions raised included: What slows down innovation in the EU, and what can be done differently? How can we ensure more investment by European companies in new pharmaceutical products? Should there be less regulation and stronger IP protection? How can #artificialintelligence revolutionize healthcare and drug development? We also witnessed a heated discussion among members of the new #EuropeanParliament about their vision for healthcare policy and the future of the pharmaceutical industry in Europe. Many thanks to EFPIA for organizing this insightful event! #WeWontRest #EFPIA #Kinstellar

The long-awaited Draghi Report was officially unveiled yesterday, and we are pleased that #ATMPs are recognised as a key area to boost EU competitiveness.   Despite the EU’s strong manufacturing and scientific capacities, Draghi concludes that the Internal Market has not kept up with the changes in the pharmaceutical landscape, particularly for innovative products.   The majority of orphan medicines and other ATMPs approved for the European market have not been developed by European-based companies, meaning most EU developers are not currently able to tap into the 8 billion global market for ATMPs.   This Report offers valuable insights into how MEPs and policymakers can expand and accelerate R&D capacities in Europe for new therapies. Ideas for change, including ATMP innovation hubs, streamlining clinical trials across the EU, and the use of AI, hold great potential for both developers and patients. We welcome opportunities to discuss what this could mean for the future of pharmaceutical innovation in a multi-stakeholder setting.   We will therefore follow closely the Report’s recommendations and how these will be taken up by the legislative proposals of the new mandate, and we look forward to working with policymakers to deliver the potential of ATMPs for EU patients.   #MEPsforATMPs #cellandgenetherapy #rarediseases #competitiveness #innovation

Healthcare is entering a defining moment, with an opportunity to embrace a new wave of innovation. Yet if Europe is to realise the full potential of these breakthroughs, it is vital that people across the region have more timely and equitable access to these treatments.   It is with this potential in mind that I take up a new position on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) – the main body representing the research-based biopharmaceutical industry in Europe.   Alongside my peers from world-leading pharmaceutical companies, I will be working to help deliver on EFPIA’s mission to create an environment that enables our industry to innovate, thrive and deliver new therapies across Europe. At Pfizer, our goal is to change the lives of one billion patients a year by 2027 – but as EFPIA’s mission alludes, this is only possible with the right policy and legislative environment in place.   Europe is often seen as a pharmaceutical powerhouse, with the skilled workforce, academic infrastructure, multi-national institutions, and manufacturing capability making it a location of choice for life science investment. Yet in spite of all this expertise and promise there is still significant inequity in access to new medicines. Patients in Europe are having to wait 517 days for access to innovative treatments on average, ranging from 128 days up to a staggering 1,351 days.* This is an unacceptable situation, and I believe our industry is and should remain an important voice in profiling and remedying this issue. Timely and equitable access is a cause I am deeply passionate about. Through my new role on the EFPIA Board, I am committed to finding and fighting for solutions in partnership with policymakers and stakeholders across Europe, based on a shared understanding of the root causes of unavailability and access delays. This is a real opportunity to create a modernised system that can embrace the next generation of medicines and vaccines. Together, I hope we can achieve a healthier and stronger Europe. * https://lnkd.in/egnbJgvd   #EFPIA #HealthPolicy #LifeSciences #HealthofEurope #MedicineAccess  

We recently had the privilege of participating in #AMMTEC2024 in Dar es Salaam last month, where stakeholders from across Africa’s pharmaceutical manufacturing ecosystem gathered to explore opportunities and challenges shaping the future of the pharmaceutical production on the continent. 🌍 Key insights from the conference included the need for #collaboration among manufacturers, funders, and policymakers to overcome barriers like financing gaps and regulatory hurdles. Discussions also emphasized the importance of #flexiblefinancing models tailored to the diverse needs of manufacturers, along with a streamlined regulatory framework that ensures quality without stifling growth.   At HFC, we are inspired by the partnerships and insights that emerged from these conversations and remain dedicated to providing solutions that not only enhance access to medicines, but also strengthen the financial health and strategic direction of the sector.   📚 Read HFC’s key takeaways from AMMTEC | African Medicines Manufacturing Trade Exhibition and Conference: https://lnkd.in/eaTgHE8M   #PharmaceuticalManufacturing #Africa #HealthFinance Colleen Connell, Alexander Honjiyo, Martin Edlund, Precious Manyara, Swathi Rao, CFA

Today, I had the honour of chairing a panel discussion at the conference we organised on health-related needs as drivers for healthcare policy and innovation.  During the panel discussion, the experts delved into ways of guiding pharmaceutical innovation in order to meet the needs of patients and society within our European healthcare system more effectively. They also discussed the financial landscape of pharmaceutical research and development, identifying obstacles and suggesting tactics to adopt a more needs-driven approach. This conference marks another crucial step ahead as we keep working together on this very important topic.

🔍 What’s stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! 🌍 Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! 🌟 Here’s our simple 3-step proposal: 1️⃣ Meet with eMQT to discuss your therapeutic area and patient population focus. 2️⃣ We identify suitable sites and countries in Africa to match your needs. 3️⃣ Collaborate with us to build Centres of Excellence! Let’s lead the way in transforming clinical research.💡🤝 #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! 🌟 https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess

🏥💊 𝗣𝗼𝗿𝘁𝘂𝗴𝗮𝗹 𝘄𝗲𝗹𝗰𝗼𝗺𝗲𝘀 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 & 𝗝𝗼𝗵𝗻𝘀𝗼𝗻'𝘀 𝗹𝗮𝘁𝗲𝘀𝘁 𝗵𝘂𝗯 - 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗮𝗳𝗲𝘁𝘆! This new addition, hosted by the Portuguese branch of Johnson & Johnson Innovative Medicine, marks a significant step towards bolstering Portugal's #pharmaceutical landscape. With a team of around 20 professionals, the hub will focus on ensuring the safety of medicines globally, tapping into the expertise of individuals with backgrounds in #medicine, #pharmacy, #biochemistry, and #biology. 🧪🔬 With these developments, Johnson & Johnson's presence in Portugal is set to expand, with approximately 240 staff members, reflecting the country's growing importance within Johnson & Johnson's global operations. Discover the latest investment updates in our Invest in Portugal newsletter. Stay informed by subscribing today: https://lnkd.in/dm7EtsGe Johnson & Johnson Innovative Medicine Portugal J&J Innovative Medicine Belgium #WhyPortugal #InvestinPortugal

Study highlights EU's fragmented access to new medicine The W.A.I.T. Indicator is a European study assessing the availability of innovative medicines and the time it takes for patients to access them. "This study highlights the disparity across European countries in the availability of novel medicines, from as little as four months to 2.5 years, showcasing the huge differences experienced by patients in neighbouring countries," said Aurelio Arias, Director of EMEA Thought Leadership at IQVIA, which conducted the study on behalf of the European pharmaceutical association, EFPIA. He told Euractiv: "The number of available medicines has also deteriorated from last year's study, with a drop of 2% in the number of medicines and an increase of 3% in the median time to availability," Arias explained. Bulgaria's bumpy progress Bulgaria provides better access to innovative medicines compared to most countries in Central and Eastern Europe, the W.A.I.T. study reveals. https://lnkd.in/e9wJJJiC #PublicHealth #Europe #StayInformed #StayEmpowered

Are you ready to tap into one of the most promising markets in the pharmaceutical industry? The West African pharma market is thriving with immense opportunities, and Pharma West Africa 2025 is your gateway to this dynamic region. Why Exhibit at Pharma West Africa 2025? • Unmatched Exposure: Showcase your products to a diverse audience of industry leaders, healthcare professionals, and key decision-makers. • Market Access: Gain direct access to the rapidly growing West African market, known for its fertile ground for pharmaceutical innovations and products. • Networking Opportunities: Connect with potential partners, distributors, and clients who are eager to explore new business opportunities. • Industry Insights: Stay ahead of market trends and gain valuable insights into the evolving needs of the West African healthcare sector. Secure your stand today and position your brand at the forefront of this vibrant market! https://lnkd.in/dhgdipt4 #PharmaWestAfrica #WestAfricanMarket #PharmaExhibition #HealthcareInnovation #ExhibitWithUs #AxessHealth

This progress underscores the crucial role SMEs play in advancing healthcare. With this framework, pharmaceutical SMEs are empowered to innovate and bring about impactful therapeutic solutions for the country. #Innovation #SME #Pharmaceuticals #EuropeanMedicinesAgency